AU2020380818A1 - Inhibitor of apoptosis (IAP) protein antagonists - Google Patents

Inhibitor of apoptosis (IAP) protein antagonists Download PDF

Info

Publication number
AU2020380818A1
AU2020380818A1 AU2020380818A AU2020380818A AU2020380818A1 AU 2020380818 A1 AU2020380818 A1 AU 2020380818A1 AU 2020380818 A AU2020380818 A AU 2020380818A AU 2020380818 A AU2020380818 A AU 2020380818A AU 2020380818 A1 AU2020380818 A1 AU 2020380818A1
Authority
AU
Australia
Prior art keywords
compound
cancer
stereoisomer
racemate
oxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020380818A
Other languages
English (en)
Inventor
Nicole BATA
Sumit Kumar CHANDA
Nicholas David Peter Cosford
Dominik HEIMANN
Lars PACHE
Peter TERIETE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanford Burnham Prebys Medical Discovery Institute
Original Assignee
Sanford Burnham Prebys Medical Discovery Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanford Burnham Prebys Medical Discovery Institute filed Critical Sanford Burnham Prebys Medical Discovery Institute
Publication of AU2020380818A1 publication Critical patent/AU2020380818A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2020380818A 2019-11-08 2020-11-06 Inhibitor of apoptosis (IAP) protein antagonists Pending AU2020380818A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962933190P 2019-11-08 2019-11-08
US62/933,190 2019-11-08
PCT/US2020/059552 WO2021092500A1 (en) 2019-11-08 2020-11-06 Inhibitor of apoptosis (iap) protein antagonists

Publications (1)

Publication Number Publication Date
AU2020380818A1 true AU2020380818A1 (en) 2022-06-02

Family

ID=75849612

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020380818A Pending AU2020380818A1 (en) 2019-11-08 2020-11-06 Inhibitor of apoptosis (IAP) protein antagonists

Country Status (6)

Country Link
US (1) US20230115837A1 (https=)
EP (1) EP4058454A4 (https=)
JP (2) JP7659553B2 (https=)
AU (1) AU2020380818A1 (https=)
CA (1) CA3160666A1 (https=)
WO (1) WO2021092500A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023246631A1 (zh) * 2022-06-22 2023-12-28 中国药科大学 一种二氮杂双环拟肽衍生物的制备方法及应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020110056A1 (en) * 2018-11-30 2020-06-04 Glaxosmithkline Intellectual Property Development Limited Compounds useful in hiv therapy
CA3160666A1 (en) * 2019-11-08 2021-05-14 Sanford Burnham Prebys Medical Discovery Institute Inhibitor of apoptosis (iap) protein antagonists
AU2021265826B2 (en) * 2020-04-30 2026-03-19 Sanford Burnham Prebys Medical Discovery Institute Inhibitor of apoptosis (IAP) protein antagonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8202902B2 (en) * 2006-05-05 2012-06-19 The Regents Of The University Of Michigan Bivalent SMAC mimetics and the uses thereof
NZ572531A (en) * 2006-05-05 2011-09-30 Univ Michigan Bivalent smac mimetics and the uses thereof
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
US8551955B2 (en) * 2009-10-28 2013-10-08 Joyant Pharmaceuticals, Inc. Dimeric Smac mimetics
US9546174B2 (en) * 2012-11-30 2017-01-17 Sanford-Burnham Medical Research Institute Inhibitor of apoptosis protein (IAP) antagonists
JP6768522B2 (ja) * 2014-06-04 2020-10-14 サンフォード−バーンハム メディカル リサーチ インスティテュート Ｈｉｖ治療におけるアポトーシスタンパク質阻害剤（ｉａｐ）のアンタゴニストの使用
KR20180107261A (ko) * 2016-02-16 2018-10-01 메사추세츠 인스티튜트 오브 테크놀로지 Myc 조정제로서의 MAX 결합제 및 그의 용도
US10870663B2 (en) * 2018-11-30 2020-12-22 Glaxosmithkline Intellectual Property Development Limited Compounds useful in HIV therapy
WO2020110056A1 (en) * 2018-11-30 2020-06-04 Glaxosmithkline Intellectual Property Development Limited Compounds useful in hiv therapy
CA3160666A1 (en) * 2019-11-08 2021-05-14 Sanford Burnham Prebys Medical Discovery Institute Inhibitor of apoptosis (iap) protein antagonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023246631A1 (zh) * 2022-06-22 2023-12-28 中国药科大学 一种二氮杂双环拟肽衍生物的制备方法及应用

Also Published As

Publication number Publication date
CA3160666A1 (en) 2021-05-14
JP2023513655A (ja) 2023-04-03
JP2025118594A (ja) 2025-08-13
EP4058454A4 (en) 2023-12-13
WO2021092500A1 (en) 2021-05-14
JP7659553B2 (ja) 2025-04-09
US20230115837A1 (en) 2023-04-13
EP4058454A1 (en) 2022-09-21

Similar Documents

Publication Publication Date Title
US11912786B2 (en) Inhibitor of apoptosis protein (IAP) antagonists
WO2020123675A1 (en) Compositions and methods for the treatment of cancer
JP7659553B2 (ja) アポトーシス阻害（ｉａｐ）タンパク質アンタゴニスト
EP2922538B1 (en) Azaindole derivatives as jak3 inhibitors
US9932329B2 (en) Benzimidazole derivatives as RLK and ITK inhibitors
WO2022246597A1 (en) Imidazopyridine derivatives as sting agonists
AU2021212770A1 (en) Strad-binding agents and uses thereof
AU2019201104A1 (en) Compounds and methods for treating cancer, neurological disorders, ethanol withdrawal, anxiety, depression and neuropathic pain
AU2021265826B2 (en) Inhibitor of apoptosis (IAP) protein antagonists
WO2023081290A1 (en) Inhibitor of apoptosis (iap) protein antagonists
WO2020028525A1 (en) Sumo inhibitor compounds and uses thereof
WO2025240412A1 (en) Methods for the treatment of cancer
WO2025240416A1 (en) Compositions and methods for the treatment of cancer
WO2024148272A1 (en) Aza bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors